ReviewAnais brasileiros de dermatologia2016
Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review.
Review in Anais brasileiros de dermatologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025).The Journal of dermatology · 2026Guideline
- A preliminary study of fractional CODermatologic therapy · 2019Trial
- Early Proteomic Alterations in Non-segmental Vitiligo Skin Following Treatment with Topical Tacrolimus.Dermatology and therapy · 2026Article
- Impacts of Topical Treatments and Phototherapy on Stratum Corneum Hydration, Sebum and Elasticity in Vitiligo Skin.Dermatology and therapy · 2025Article
- The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- Antioxidant mechanisms of mesenchymal stem cells and their therapeutic potential in vitiligo.Frontiers in cell and developmental biology · 2023Review
- The Role of MicroRNAs in Vitiligo: Regulators and Therapeutic Targets.Annals of dermatology · 2020Review
- Macrophage inhibitory factor (MIF) gene polymorphisms are associated with disease susceptibility and with circulating MIF levels in active non-segmental vitiligo in patients from western Mexico.Molecular genetics & genomic medicine · 2020Article
- Treatment Strategies for Hypopigmentation in the Context of Burn Hypertrophic Scars.Plastic and reconstructive surgery. Global open · 2018Article
- Trends in Regenerative Medicine: Repigmentation in Vitiligo Through Melanocyte Stem Cell Mobilization.Medicinal research reviews · 2017Review
- Effectiveness and safety of topical tacrolimus in treatment of vitiligo.Journal of advanced pharmaceutical technology & researchArticle
- Recent Advances in Management of Vitiligo.Indian journal of dermatologyReview
- Melanogenesis and Hypopigmentation: The Case of Vitiligo.Indian journal of dermatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thus far, several small studies and case reports on the use of topical immunomodulators in vitiligo have been published. We undertook a comprehensive literature review, searching for studies evaluating clinical response to tacrolimus topical therapy for vitiligo. A search was performed on PubMed/Medline using the term "vitiligo", combined with "topical" and "ointment". Our inclusion criteria were: use of tacrolimus ointment as monotherapy to treat vitiligo. We found 29 studies from 2002 to 2014. Overall, 709 patients were treated in 29 studies. Pooling the lesions, 50% repigmentation of vitiligo patches was never achieved before 2 months of treatment, with a peak after 6 months of therapy. The best results were obtained on lesions of the cephalic region, especially the face, with tacrolimus 0.1% ointment two times daily. The percentage of non-responsive patients ranged from 0% to 14%. Treatment was generally well-tolerated; only localized adverse effects were reported. Our objective was to verify the effectiveness and safety of tacrolimus ointment monotherapy. It has good efficacy and tolerability. At present, only small trials and case series are available in the literature. Further, standardized investigations on a larger number of patients are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.